Riverbridge Partners LLC Has $23.06 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Riverbridge Partners LLC reduced its holdings in Certara, Inc. (NASDAQ:CERT) by 9.8% in the 4th quarter, HoldingsChannel reports. The fund owned 2,164,747 shares of the company’s stock after selling 236,171 shares during the period. Riverbridge Partners LLC’s holdings in Certara were worth $23,055,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of CERT. Blue Trust Inc. grew its stake in shares of Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after purchasing an additional 2,076 shares during the last quarter. KBC Group NV increased its stake in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after buying an additional 1,584 shares during the period. GAMMA Investing LLC raised its position in shares of Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock worth $90,000 after acquiring an additional 6,868 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Certara in the second quarter worth approximately $152,000. Finally, Algert Global LLC bought a new stake in Certara in the second quarter valued at approximately $156,000. Institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

CERT has been the topic of a number of recent analyst reports. Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Robert W. Baird cut their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Finally, UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.92.

Certara Stock Up 3.0 %

NASDAQ:CERT opened at $12.99 on Thursday. The firm has a fifty day simple moving average of $11.01 and a two-hundred day simple moving average of $11.89. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period last year, the business posted $0.06 EPS. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. As a group, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.